Determinants of COVID-19 vaccine fatigue

Abstract

There is growing concern that Coronavirus Disease 2019 (COVID-19) vaccine fatigue will be a major obstacle in maintaining immunity in the general population. In this study, we assessed vaccine acceptance in future scenarios in two conjoint experiments, investigating determinants such as new vaccines, communication, costs/incentives and legal rules. The experiments were embedded in an online survey (n = 6,357 participants) conducted in two European countries (Austria and Italy). Our results suggest that vaccination campaigns should be tailored to subgroups based on their vaccination status. Among the unvaccinated, campaign messages conveying community spirit had a positive effect (0.343, confidence interval (CI) 0.019–0.666), whereas offering positive incentives, such as a cash reward (0.722, CI 0.429–1.014) or voucher (0.670, CI 0.373–0.967), was pivotal to the decision-making of those vaccinated once or twice. Among the triple vaccinated, vaccination readiness increased when adapted vaccines were offered (0.279, CI 0.182–0.377), but costs (−0.795, CI −0.935 to −0.654) and medical dissensus (−0.161, CI −0.293 to −0.030) reduced their likelihood to get vaccinated. We conclude that failing to mobilize the triple vaccinated is likely to result in booster vaccination rates falling short of expectations. For long-term success, measures fostering institutional trust should be considered. These results provide guidance to those responsible for future COVID-19 vaccination campaigns.

Between information campaign and controversy: a quantitative newspaper content analysis about COVID-19 vaccination in Switzerland and Austria

“…Mass media undoubtedly form part of this social context, and longitudinal analyses could thus help to understand why attitudes may change over time. Our analysis also speaks to the relevance of traditional mass media regarding willingness to vaccinate as well as the important function of journalistically edited media and their potential in shaping perceptions of the pandemic [36,37].…”

Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden

“…In the ongoing 2023/2024 winter, only 30% of seniors have received an additional booster dose as of February 4, 2024 44 . Effective communication and recommendations incentivizing vaccination are needed to overcome vaccine fatigue 45 , maximize booster coverage, and limit the significant hospitalizations that COVID-19 continues to cause.…”

Humoral and cellular immune responses analysis using FTIR spectroscopy on newborns of mothers vaccinated against COVID-19 with mRNA or viral vector vaccine

“…1,2 The scarcity of an effective treatment and its virulence converted the vaccines into an essential tool to face this pandemic. 3 Vaccination provides the best way to protect against COVID-19 and its complications and has been widely available in many countries. 3,4 It is well known that there are different categories of vaccines, such as DNA, mRNA, inactivated, live attenuated, virion-like particle, viral vector, recombinant subunit, and synthetic peptide.…”

“…3 Vaccination provides the best way to protect against COVID-19 and its complications and has been widely available in many countries. 3,4 It is well known that there are different categories of vaccines, such as DNA, mRNA, inactivated, live attenuated, virion-like particle, viral vector, recombinant subunit, and synthetic peptide. 5 Different vaccines were developed in the ght against the COVID-19 outbreak; the main and most used vaccines were the mRNA vaccines by P zer-BioNTech [Comirnaty] and Modern, as well as CureVac.…”